scholarly journals An Assessment of the Reporting Pattern of Adverse Events Following Immunizations in VigiAccess

2018 ◽  
Vol 10 (11) ◽  
pp. 46 ◽  
Author(s):  
Peter Yamoah ◽  
Frasia Oosthuizen
Keyword(s):  
Adverse Events ◽  
Subcutaneous Tissue ◽  
Oral Polio Vaccine ◽  
Vaccine Safety ◽  
Yellow Fever Vaccine ◽  
Data Synchronization ◽  
Site Conditions ◽  
The World ◽  
Pharmacovigilance Database ◽  
Reporting Pattern

PURPOSE: Globally, adverse events following immunization (AEFI) reporting continues to be a challenge. It is estimated that about 95% of AEFIs never get reported after vaccinations necessitating strategies to improve it. The introduction of databases such as VigiAccess in which AEFI data from Pharmacovigilance centres around the world can be assessed is an important step towards improving AEFI reporting and enhancing vaccine safety. This study assessed the reporting pattern of AEFIs from the various continents of the world in VigiAccess, an open-access pharmacovigilance database. METHODS: VigiAccess was thoroughly searched on the 5th of February 2018 for the categories of reported AEFIs and number and types of AEFIs reported for measles vaccine, oral polio vaccine, yellow fever vaccine, pneumococcal vaccine, rotavirus vaccine, meningococcal vaccine, tetanus vaccine and BCG vaccine. RESULTS: After a thorough search through VigiAccess, 27 categories of reported AEFIs were retrieved. The total number of AEFIs for the 8 vaccines was 813,973. General disorders and administration site conditions were the highest number of AEFIs (251,405 representing 30.9%) followed by skin and subcutaneous tissue disorders (93,011 representing 11.4%) and nervous system disorders (89,077 representing 10.9%). With the continental data, the Americas recorded the highest number of AEFIs followed by Europe, Oceania, Asia and Africa. CONCLUSION: General and vaccine administration site conditions were the highest number of AEFIs. The Americas recorded the highest number of AEFIs whereas Africa recorded the least. VigiAccess needs improvement in data synchronization to enhance its reliability.

scholarly journals Associations between osteoporosis and drug exposure: a post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®)

Bone ◽  
2021 ◽  
pp. 116137
Author(s):  
Benjamin Batteux ◽  
Youssef Bennis ◽  
Sandra Bodeau ◽  
Kamel Masmoudi ◽  
Anne-Sophie Hurtel-Lemaire ◽  
...  
Keyword(s):  
World Health Organization ◽  
Drug Exposure ◽  
World Health ◽  
The World ◽  
Pharmacovigilance Database ◽  
Post Marketing ◽  
Health Organization

scholarly journals POS0815 CLINICAL CHARACTERISTICS, IMAGING PHENOTYPE, AND LONG-TERM OUTCOMES OF TAKAYASU ARTERITIS PATIENTS WITH HYPERTENSION

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 661.1-661
Author(s):  
Y. Sun ◽  
L. Ma ◽  
H. Chen ◽  
C. Rongyi ◽  
L. Jiang
Keyword(s):  
Blood Pressure ◽  
Adverse Events ◽  
Clinical Features ◽  
Takayasu Arteritis ◽  
Pressure Control ◽  
Free Survival ◽  
The World ◽  
Cluster 2

Background:Hypertension occurred in 30-80% of TAK patients around the world. The occurrence of hypertension might severely worsen TAK prognosis. Nevertheless, data describing the specific imaging features in hypertensive TAK patients and the associations between hypertensive severity, blood pressure control status and long-term outcome were still lacking.Objectives:To investigate the characteristics and associations of hypertensive characteristics with adverse events-free survival in Takayasu arteritis (TAK) patients with hypertension.Methods:This research was based on a prospectively on-going observational cohort-East China Takayasu Arteritis (ECTA) cohort. In all, 618 TAK patients, who registered in the ECTA cohort up to December 2019, were enrolled. The main outcome was the adverse-events-free survival among hypertensive TAK patients during the follow-up ended on August 2020.Results:Totally, 204 (33.0%) patients suffered from hypertension, with 48 (23.5%), 62 (30.4%), and 94 (46.1%) mild, moderate, and severe hypertension, respectively. Cluster analysis indicated three imaging phenotypes for hypertensive TAK patients: Cluster 1: involvement of the abdominal aorta and/or renal artery (n=56, 27.5%); Cluster 2: involvement of the ascending aorta, thoracic aorta, and the aortic arch and its branches (n=38, 18.6%); Cluster 3: combined involvement of Cluster 1 and Cluster 2 (n=111, 54.4%). By the end of the follow-up, the blood pressure control rate was 50.8%, while the adverse-events-free survival was 67.9% in the entire hypertensive population. Multivariate Cox regression analysis indicated that well-controlled blood pressure (HR=2.13, 95%CI 1.32–3.78, p=0.047), co-existence of severe aortic valve regurgitation (HR=0.87, 95%CI 0.64–0.95, p=0.043), Cluster 1 (HR=0.69, 95%CI 0.48–0.92, p=0.017) and Cluster 3 (HR=0.72, 95%CI 0.43–0.94, p=0.048) imaging phenotype was associated with the adverse-events-free survival.Conclusion:Patients with controlled hypertension showed better adverse-events-free survival, while those with the Cluster 1 imaging phenotype were more likely to suffer from worse adverse-events-free survival. Hypertension occurred in 30-80% of TAK patients around the world. The occurrence of hypertension might severely worsen TAK prognosis.References:[1]Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. J Clin Pathol 2002; 55:481–6.[2]Watanabe Y, Miyata T, Tanemoto K. Current clinical features of new patients with Takayasu arteritis observed from a cross-country research in Japan: age and sex specificity. Circulation 2015; 132:1701–9.[3]Yilmaz N, Can M, Oner FA, et al. Impaired quality of life, disability and mental health in Takayasu’s arteritis. Rheumatol. (Oxford) 2013; 52:1898–904.[4]Laurent A, Julien H, Nicolas L, et al. Takayasu arteritis in France: a single-center retrospective study of 82 cases comparing white, North African, and black patients. Medicine 2010; 89:1–17.[5]Mwipatayi BP, Jeffery PC, Beningfield SJ, et al. Takayasu arteritis: clinical features and management: report of 272 cases. ANZ J Surg 2005; 75:110–7.Disclosure of Interests:None declared

scholarly journals Recombinant Human Adenovirus-p53 Therapy for the Treatment of Oral Leukoplakia and Oral Squamous Cell Carcinoma: A Systematic Review

Medicina ◽  
2021 ◽  
Vol 57 (5) ◽  
pp. 438
Author(s):  
Jagadish Hosmani ◽  
Shazia Mushtaq ◽  
Shahabe Saquib Abullais ◽  
Hussain Mohammed Almubarak ◽  
Khalil Assiri ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Oral Cancer ◽  
Adverse Events ◽  
Randomized Clinical Trials ◽  
Oral Leukoplakia ◽  
Research Articles ◽  
Original Research ◽  
Therapeutic Effects ◽  
The World

Background and Objectives: Oral cancer is the 6th most common cancer in the world and oral leukoplakia is an oral potentially malignant disorder that could develop into oral cancer. This systematic review focusses on randomized clinical trials for recombinant adenovirus p-53 (rAD-p53) therapy for the treatment of oral leukoplakia and cancer. Materials and Methods: We searched for research articles on various databases such as Pubmed/Medline, Embase, CNKI (China National Knowledge Infra-structure), Springerlink, cochrane and Web of sciences from 2003 to 2020. MeSH (Medical Subject Headings) terms were used for the search. Inclusion criteria included original research, randomized clinical trials and articles only in English language. Exclusion criteria were any articles that were not research articles, not randomized trials, non-human studies, etc. The articles were further graded on the Jadad scale. Results: 578 articles were assessed from various databases; only 3 articles were found to be appropriate for this review. Thus, meta-analysis was not performed because of heterogeneity and lack of data. In the three studies, whether rAD-p53 was used as a standalone therapy or with other therapies, there was a beneficial effect of the therapy. Furthermore, there were no serious adverse events and the only adverse events reported were fever, pain at the local injection site, flu-like symptoms and lowered WBC count. Conclusions: Thus, we can conclude that this therapy has a potential for beneficial therapeutic effects and further clinical trials with more patients need to be performed to get better understanding of the effect of rAD-p53 therapy, which probably will pave the way to its approval in other parts of the world.

scholarly journals Adverse events of the yellow fever vaccine in chronic urticaria: evaluation of patients treated or not with omalizumab compared to healthy individuals

2021 ◽  
Author(s):  
Laura Ramos de Almeida ◽  
Roberta Fachini Criado ◽  
Paulo Ricardo Criado ◽  
Luis Felipe Ensina ◽  
Beatrice Martinez Zugaib Abdalla ◽  
...  
Keyword(s):  
Adverse Events ◽  
Yellow Fever ◽  
Chronic Urticaria ◽  
Yellow Fever Vaccine ◽  
Healthy Individuals

Vaccine Safety and Surveillance for Adverse Events Following Immunization (AEFI) in India

2017 ◽  
Vol 85 (2) ◽  
pp. 139-148 ◽  
Author(s):  
Jyoti Joshi ◽  
Manoja Kumar Das ◽  
Deepak Polpakara ◽  
Satinder Aneja ◽  
Mahesh Agarwal ◽  
...  
Keyword(s):  
Adverse Events ◽  
Vaccine Safety

Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study

2021 ◽  
Vol 184 (3) ◽  
pp. 441-448
Author(s):  
Luc Pijnenburg ◽  
Joe-Elie Salem ◽  
Bénédicte Lebrun-Vignes ◽  
Jean Sibilia ◽  
Rose-Marie Javier ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Zoledronic Acid ◽  
Pamidronic Acid ◽  
Real Life ◽  
World Health ◽  
Disproportionality Analysis ◽  
Pharmacoepidemiological Study ◽  
Systematic Analysis ◽  
The World ◽  
Pharmacovigilance Database

Objective Atrial fibrillation (AF) may be triggered by intravenous bisphosphonates (IVBPs) such as zoledronic acid or pamidronic acid. Our objective was to confirm the association between AF and IVBPs in a real-life large pharmacovigilance database. Design A systematic analysis of VigiBase, the World Health Organization's pharmacovigilance database. Methods Analysis of adverse events reported as ‘atrial fibrillation’ (according to the Medical Dictionary for Drug Regulatory Activities) associated with the use of zoledronic acid or pamidronic acid, in VigiBase, the World Health Organization's global Individual Case Safety Report (ICSR) database. All ICSRs reporting AF associated with zoledronic acid or pamidronic acid were included in a disproportionality analysis determining the lower end of the 95% credibility interval for the information component (IC025), showing a statistical association when >0. Results 530 ICSRs reporting on the association between AF and IVBPs were extracted. Bayesian disproportionality analysis detected a significant association between AF and use of zoledronic acid (IC025 = 1.83) and pamidronic acid (IC025 = 2.16). Further analysis of these ICSRs determined that AF was severe in 85.0% of cases and with a mortality of 17.7%. The risk of severe AF was increased (OR: 2.98 (95% CI: 1.17–7.57), P = 0.02) following zoledronic acid vs pamidronic acid, after adjustment for age and gender. Conclusions This is the first VigiBase pharmacoepidemiological study confirming the association between IVBPs and AF. Most AF were severe, with a high frequency of lethal outcome. The risk of severe AF was increased following zoledronic acid use compared to pamidronic acid, advocating for a cautious use of IVBPs.

Response to Austriaco on Vaccine Passports

2021 ◽  
Vol 46 (4) ◽  
pp. 4-4
Author(s):  
Joseph Meaney ◽  
Keyword(s):  
World Health Organization ◽  
Cell Lines ◽  
Yellow Fever ◽  
International Travel ◽  
World Health ◽  
Yellow Fever Vaccine ◽  
Work Activities ◽  
The World ◽  
Health Organization

This essay clarifies the author’s objections to COVID-19 vaccine credentials voiced in “The Ethics of COVID-19 Vaccine Passports.” The author’s objections centered on discriminatory practices based on vaccine status for domestic social and work activities, but he agrees with the World Health Organization that these credentials should not be required for international travel. In addition, there is a significant ethical different between currently available COVID-19 vaccines and the yellow fever vaccine because the former are produced or tested using abortion-derived cell lines. The yellow fever vaccine is much less ethically problematic. This situation could change with the approval of new COVID-19 vaccines without links to abortion-derived cell lines.

scholarly journals Safety and Immunogenicity of Live Oral Cholera and Typhoid Vaccines Administered Alone or in Combination with Antimalarial Drugs, Oral Polio Vaccine, or Yellow Fever Vaccine

1997 ◽  
Vol 175 (4) ◽  
pp. 871-875 ◽  
Author(s):  
Herwig Kollaritsch ◽  
John U. Que ◽  
Christian Kunz ◽  
Gerhard Wiedermann ◽  
Christian Herzog ◽  
...  
Keyword(s):  
Yellow Fever ◽  
Oral Polio Vaccine ◽  
Antimalarial Drugs ◽  
Yellow Fever Vaccine ◽  
Polio Vaccine ◽  
Typhoid Vaccines
Sign in / Sign up

Export Citation Format

Share Document